Parvus Therapeutics Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Parvus Therapeutics Inc.
Deal Watch: Altimmune Moves Into NASH With Purchase Of Spitfire
Currently focused on HBV, Altimmune gets preclinical NASH candidate that offers dual agonism of GLP-1 and glucagon receptors. Nimbus expands alliance with Celgene into IO, Merck & Co. partners with Skyhawk.
Roche Dealmakers On The Immunology Technology They're Shopping For
Business development execs Patrick Schleck and Michael Crowley talk to Scrip about the company’s recent deals with Parvus, Jecure and Microbiotica in the inflammatory and autoimmune disease space.
Deal Watch: Parvus Signs Second Big Pharma Alliance, With Genentech
Two years after its first big Navacim-based tie-up with Novartis, Parvus could earn beyond $800m in autoimmune R&D pact with Genentech. Iconic licenses ADC tech from Zymeworks, then out-licenses lead candidate to Exelixis.
Parvus Seeks Autoimmune Answers Through Restoring Immune Tolerance
Emerging Company Profile: Partnered with Novartis on a nanoparticle candidate for type 1 diabetes, Parvus develops its proprietary Navacims to help the body’s immune system differ between a pathogen and itself.
- Large Molecule
- Nanotechnology, Chips, etc.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.